The New Era of Inflammatory Disease Management Through the Application of Biosimilar Therapeutics
CPE Symposium in Conjunction with the Academy of Managed Care Pharmacy 2023 Meeting
Thursday, March 23rd, 2023
Registration and Dinner | 6:00pm – 6:30pm CT
CPE Symposium | 6:30pm – 8:00pm CT
Henry B. Gonzalez Convention Center
900 E Market Street
San Antonio, TX 78205
While biosimilar therapeutics have been widely available for some time for the treatment inflammatory conditions, many pharmacists, managed care professionals, and other healthcare providers have not had a recent opportunity to investigate data showing the interchangeable safety and efficacy alignment between approved biosimilar therapeutics and their less accessible referent medications. In addition to interchangeability, concepts involving extrapolation and the shifting of a treatment plan to include biosimilar equivalents may not have made clear inroads into the daily practice of those involved in medication distribution and formulary management. A clinical update on these concepts for pharmacists, managed care professionals, and related healthcare providers, can help reduce or remove serious barriers to care affecting patients with inflammatory bowel and joint diseases.
I. Welcome and Introductions – Shubha Bhat, PharmD
II. Biosimilar Therapies for Inflammatory Disease: Pharmacologic Developmental Process and Assessment of Available Treatments – Shubha Bhat, PharmD and Amaneul Kehasse, PharmD
III. Clinical Trial Data Update and Practical Approaches for the Use of Biosimilars, Including Interchangeability and Switching – Amaneul Kehasse, PharmD
IV. The Pharmacist and Managed Care Professional’s Role in Patient Education, Including Issues of Varying Patient Perceptions – Adam Cheifetz, MD and Shubha Bhat, PharmD
V. Interactive Faculty Panel Discussion – All Faculty
1. Review current information on the developmental and clinical trial process of biosimilar therapies and recent advances in the use of biosimilars to treat inflammatory bowel disease and rheumatological disorders.
2. Analyze recent clinical trial data and review practical approaches for the use of biosimilars, including interchangeability and switching.
3. Develop strategies to communicate with the interprofessional team and educate patients on biosimilars, including issues of varying patient perceptions.
Shubha Bhat, PharmD
Clinical Pharmacy Specialist, Gastroenterology
Digestive Disease & Surgery Institute
Adam S. Cheifetz, MD
Professor of Medicine
Harvard Medical School
Director, Center for Inflammatory Bowel Disease
Beth Israel Deaconess Medical Center
Amanuel Kehasse, PharmD, PhD
Clinical Pharmacy Specialist in Rheumatology,
Dermatology, and Interstitial Lung Disease
Boston Medical Center Health System
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Pharmacy Education (ACPE), the Accreditation Council for Continuing Medical Education (ACCME), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement
AcademicCME designates this continuing education activity for 1.50 CPE Contact Hour (0.15 CEUs) of continuing pharmacy education credit (UAN JA4008190-0000-23-002-L01-P).
AcademicCME designates this live material for a maximum of 1.50 AMA PRA Category 1 CreditsTM.
Participants should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs:
For all CE inquiries or special needs, please contact [email protected] or 610-687-3300.
This activity is supported by an independent educational grant from Pfizer Inc.